JPH08242883A - Monoclonal antibody against 2-mthylisoborneol, its production and measurement of 2-methylisoborneol with the same - Google Patents
Monoclonal antibody against 2-mthylisoborneol, its production and measurement of 2-methylisoborneol with the sameInfo
- Publication number
- JPH08242883A JPH08242883A JP7078364A JP7836495A JPH08242883A JP H08242883 A JPH08242883 A JP H08242883A JP 7078364 A JP7078364 A JP 7078364A JP 7836495 A JP7836495 A JP 7836495A JP H08242883 A JPH08242883 A JP H08242883A
- Authority
- JP
- Japan
- Prior art keywords
- monoclonal antibody
- 2mib
- hybridoma
- methylisoborneol
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 title claims abstract description 28
- LFYXNXGVLGKVCJ-FBIMIBRVSA-N 2-methylisoborneol Chemical compound C1C[C@@]2(C)[C@](C)(O)C[C@@H]1C2(C)C LFYXNXGVLGKVCJ-FBIMIBRVSA-N 0.000 title claims abstract description 25
- LFYXNXGVLGKVCJ-UHFFFAOYSA-N 2-methylisoborneol Natural products C1CC2(C)C(C)(O)CC1C2(C)C LFYXNXGVLGKVCJ-UHFFFAOYSA-N 0.000 title claims abstract description 21
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 16
- 238000005259 measurement Methods 0.000 title abstract description 12
- 238000000034 method Methods 0.000 claims abstract description 49
- 210000004408 hybridoma Anatomy 0.000 claims abstract description 44
- 239000000427 antigen Substances 0.000 claims abstract description 18
- 108091007433 antigens Proteins 0.000 claims abstract description 18
- 102000036639 antigens Human genes 0.000 claims abstract description 18
- 210000004027 cell Anatomy 0.000 claims abstract description 14
- 241001465754 Metazoa Species 0.000 claims abstract description 13
- 206010035226 Plasma cell myeloma Diseases 0.000 claims abstract description 11
- 201000000050 myeloid neoplasm Diseases 0.000 claims abstract description 11
- 150000001875 compounds Chemical class 0.000 claims abstract description 9
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical group C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims description 15
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims description 15
- DTGKSKDOIYIVQL-MRTMQBJTSA-N Isoborneol Natural products C1C[C@@]2(C)[C@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-MRTMQBJTSA-N 0.000 claims description 13
- 230000007910 cell fusion Effects 0.000 claims description 8
- 230000008105 immune reaction Effects 0.000 claims description 5
- 210000002751 lymph Anatomy 0.000 claims description 3
- -1 2-methylisoborneol analog compound Chemical class 0.000 claims description 2
- 210000004698 lymphocyte Anatomy 0.000 abstract description 5
- 230000035945 sensitivity Effects 0.000 abstract description 5
- 238000012258 culturing Methods 0.000 abstract description 4
- 239000000243 solution Substances 0.000 description 16
- 239000002609 medium Substances 0.000 description 14
- 230000003053 immunization Effects 0.000 description 13
- 239000012228 culture supernatant Substances 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 10
- 239000002953 phosphate buffered saline Substances 0.000 description 10
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 238000010367 cloning Methods 0.000 description 8
- 238000002649 immunization Methods 0.000 description 7
- 238000003018 immunoassay Methods 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 5
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 108010058846 Ovalbumin Proteins 0.000 description 5
- 229940098773 bovine serum albumin Drugs 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000007758 minimum essential medium Substances 0.000 description 5
- 229940092253 ovalbumin Drugs 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 4
- 206010003445 Ascites Diseases 0.000 description 4
- 241000723346 Cinnamomum camphora Species 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 229930008380 camphor Natural products 0.000 description 4
- 229960000846 camphor Drugs 0.000 description 4
- 239000012894 fetal calf serum Substances 0.000 description 4
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 210000000683 abdominal cavity Anatomy 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- 210000000628 antibody-producing cell Anatomy 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000003113 dilution method Methods 0.000 description 3
- VANNPISTIUFMLH-UHFFFAOYSA-N glutaric anhydride Chemical compound O=C1CCCC(=O)O1 VANNPISTIUFMLH-UHFFFAOYSA-N 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000003127 radioimmunoassay Methods 0.000 description 3
- 102220201851 rs143406017 Human genes 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 description 2
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 2
- 241000186361 Actinobacteria <class> Species 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- 101000945496 Homo sapiens Proliferation marker protein Ki-67 Proteins 0.000 description 2
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 102100034836 Proliferation marker protein Ki-67 Human genes 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 101710120037 Toxin CcdB Proteins 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 229960003896 aminopterin Drugs 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 229940116229 borneol Drugs 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000005757 colony formation Effects 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- ZQTYQMYDIHMKQB-UHFFFAOYSA-N exo-norborneol Chemical compound C1CC2C(O)CC1C2 ZQTYQMYDIHMKQB-UHFFFAOYSA-N 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 2
- 108060003552 hemocyanin Proteins 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- KPMKEVXVVHNIEY-RITPCOANSA-N norcamphor Chemical compound C1C[C@@H]2C(=O)C[C@H]1C2 KPMKEVXVVHNIEY-RITPCOANSA-N 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000003393 splenic effect Effects 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
- GZSOSUNBTXMUFQ-NJGQXECBSA-N 5,7,3'-Trihydroxy-4'-methoxyflavone 7-O-rutinoside Natural products O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2cc(O)c3C(=O)C=C(c4cc(O)c(OC)cc4)Oc3c2)O1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1 GZSOSUNBTXMUFQ-NJGQXECBSA-N 0.000 description 1
- LPXQRXLUHJKZIE-UHFFFAOYSA-N 8-azaguanine Chemical compound NC1=NC(O)=C2NN=NC2=N1 LPXQRXLUHJKZIE-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108700010388 MIBs Proteins 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 239000003905 agrochemical Substances 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- GZSOSUNBTXMUFQ-YFAPSIMESA-N diosmin Chemical compound C1=C(O)C(OC)=CC=C1C(OC1=C2)=CC(=O)C1=C(O)C=C2O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)O1 GZSOSUNBTXMUFQ-YFAPSIMESA-N 0.000 description 1
- 229960004352 diosmin Drugs 0.000 description 1
- IGBKNLGEMMEWKD-UHFFFAOYSA-N diosmin Natural products COc1ccc(cc1)C2=C(O)C(=O)c3c(O)cc(OC4OC(COC5OC(C)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 IGBKNLGEMMEWKD-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000003891 environmental analysis Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000012851 eutrophication Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229940027941 immunoglobulin g Drugs 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000006298 mdm Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229940014800 succinic anhydride Drugs 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Landscapes
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
【0001】[0001]
【産業上の利用分野】本発明は、水道水中の異臭味原因
物質の一つである2−メチルイソボルネオール(以下2
MIBと称する)に対して特異的に反応するモノクロー
ナル抗体、その製造方法およびそのモノクローナル抗体
を用いる2MIBの測定方法に関する。BACKGROUND OF THE INVENTION The present invention relates to 2-methylisoborneol (hereinafter referred to as 2) which is one of the substances causing off-flavor in tap water.
(Referred to as MIB), a method for producing the same, and a method for measuring 2MIB using the monoclonal antibody.
【0002】[0002]
【従来の技術】近年、河川や湖沼などの富栄養化から各
種の藻類や微生物が異常増殖し、そのため発生する臭気
が、これらの水域を水源とする上水道に大きな影響を及
ぼし、問題となっている。中でも2MIBは、かび臭を
もたらす物質の一つとして問題になり、水道法における
快適水質項目にも挙げられている。この2MIBの測定
法としては、一般にガスクロマトグラフィーやガスクロ
マトグラフィー・マススペクトロメトリーなどの高価な
測定装置が用いられる。またパージトラップ法という濃
縮法を用いるため測定装置に特殊な濃縮装置を装着する
必要がある。また1サンプル当たりの測定時間も2時間
程度必要とする。そのため、細かい監視体制の構築を困
難にしている。2. Description of the Related Art In recent years, various algae and microorganisms have abnormally proliferated due to eutrophication of rivers and lakes, and the odor generated thereby has a great influence on waterworks using these water bodies as a water source, which has become a problem. There is. Among them, 2MIB has become a problem as one of the substances that cause musty odor, and it is also listed in the comfortable water quality item in the Waterworks Law. As a method for measuring 2MIB, an expensive measuring device such as gas chromatography or gas chromatography / mass spectrometry is generally used. In addition, since a concentration method called the purge trap method is used, it is necessary to equip the measuring device with a special concentration device. Also, the measurement time for one sample is about 2 hours. Therefore, it is difficult to build a detailed monitoring system.
【0003】一方免疫測定法は、迅速且つ誰にでも簡単
に操作でき、多検体同時測定も可能であることから、医
療・臨床検査に盛んに使用されている。また最近では農
薬などの環境分析にも応用されるようになった。2MI
Bにおいても免疫測定法が開発されれば、簡単迅速に多
検体測定を行うことが可能となることから、全国各地の
水源におけるモニタリングなどに極めて有効であると考
えられた。On the other hand, the immunoassay method is rapidly and easily operated by anyone, and simultaneous measurement of multiple specimens is possible. Therefore, the immunoassay method is widely used in medical and clinical examinations. Recently, it has also been applied to environmental analysis of agricultural chemicals. 2 MI
If the immunoassay method was developed in B as well, it would be possible to easily and quickly perform multi-specimen measurement, so it was considered to be extremely effective for monitoring in water sources throughout Japan.
【0004】このような試みとしては、兎ポリクローナ
ル抗体を用いる方法(J.Agric.Food Ch
em.38、410〜415(1990))が知られて
いる。2MIBのような低分子に対する抗体を作製する
場合は、それ自身が免疫原性を持たないため、一般に蛋
白質などの高分子物質と結合させて、これを免疫用抗原
として動物を免疫する必要がある。ポリクローナル抗体
の場合、この免疫用抗原のロット差や免疫する動物の固
体差、及び免疫の仕方などによって、その都度抗体力
価、親和性、特異性及び抗体サブクラスなどの諸性質の
異なる抗体が得られるため、2MIBの測定結果に不安
定性等種々の影響が生じた。As such an attempt, a method using a rabbit polyclonal antibody (J. Agric. Food Ch
em. 38 , 410-415 (1990)). When producing an antibody against a small molecule such as 2MIB, since it does not have immunogenicity by itself, it is generally necessary to bind it to a high molecular substance such as a protein and immunize an animal with this as an immunizing antigen. . In the case of a polyclonal antibody, antibodies with different properties such as antibody titer, affinity, specificity and antibody subclass are obtained each time depending on the lot difference of the immunizing antigen, the individual difference of the immunized animal, and the immunization method. Therefore, various effects such as instability occurred on the measurement result of 2MIB.
【0005】[0005]
【発明が解決しょうとする課題】以上のように、免疫学
的に2MIBを測定しようとする場合には有効な抗体が
必要であるが、前記のように十分な抗体は得られていな
かった。本発明は2MIBと特異的に免疫反応する新規
モノクローナル抗体を提供するとともに、該モノクロー
ナル抗体を用いて水中の2MIBを感度よくかつ迅速に
測定しうる方法を提供することを課題とするものであ
る。As described above, an effective antibody is required for immunologically measuring 2MIB, but as described above, a sufficient antibody has not been obtained. An object of the present invention is to provide a novel monoclonal antibody that specifically immunoreacts with 2MIB, and a method capable of sensitively and rapidly measuring 2MIB in water using the monoclonal antibody.
【0006】[0006]
【課題を解決するための手段】上記課題を解決するため
に、本発明は2MIBと特異的に免疫反応するモノクロ
ーナル抗体及びその製造方法、ならびに該モノクローナ
ル抗体を産生するハイブリドーマ、該ハイブリドーマの
製造方法、ならびに該モノクローナル抗体を用いて水中
の2MIBを感度よくかつ迅速に測定し得る方法を提供
するものである。In order to solve the above problems, the present invention provides a monoclonal antibody which specifically immunoreacts with 2MIB, a method for producing the same, a hybridoma producing the monoclonal antibody, a method for producing the hybridoma, It also provides a method capable of sensitively and rapidly measuring 2MIB in water using the monoclonal antibody.
【0007】以下、本発明について詳細に説明する。The present invention will be described in detail below.
【0008】本発明の第1は、2MIBに対して特異的
に免疫反応することを特徴とするモノクローナル抗体で
ある。該モノクローナル抗体は正確には2MIB類似化
合物、即ち2MIB以外にもイソボルネオール(以下I
Bと称する)、ボルネオール、カンファーとも反応し、
ノルボルネオール、ノルカンファーとは実質的に反応せ
ず、特に2MIBの測定感度が5ng/アッセイのレベ
ルにあるモノクローナル抗体である。本発明の第2は、
2−メチルイソボルネオールまたはその類似化合物をハ
プテンとした抗原であらかじめ免疫された動物のリンパ
細胞とミエローマ細胞との細胞融合により作製されたハ
イブリドーマのなかから2−メチルイソボルネオールと
特異的に免疫反応を示すモノクローナル抗体を産生する
ハイブリドーマを選択し、該ハイブリドーマを培養する
ことを特徴とする前記のモノクローナル抗体の製造方法
である。本発明の第3は、前記2MIBの類似化合物が
IBであることを特徴とする前記のモノクローナル抗体
の製造方法である。本発明の第4は、前記のモノクロー
ナル抗体を産生するハイブリドーマである。本発明の第
5は、2MIBまたはその類似化合物をハプテンとした
抗原であらかじめ免疫された動物のリンパ細胞とミエロ
ーマ細胞との細胞融合により作製されたハイブリドーマ
のなかから、2MIBに対して特異的に免疫反応を示す
モノクローナル抗体を産生するハイブリドーマを選択す
ることを特徴とする前記ハイブリドーマの作製法であ
る。本発明の第6は、前記2MIBの類似化合物がIB
である前記ハイブリドーマの作製法である。本発明の第
7は、前記モノクローナル抗体を用いることを特徴とす
る2−メチルイソボルネオールの測定方法である。この
測定方法は環境中の2MIBの測定、ひいては臭気・異
味等の測定に好適で、特に上水道分野での利用が期待さ
れる。The first aspect of the present invention is a monoclonal antibody characterized by specifically immunoreacting with 2MIB. To be exact, the monoclonal antibody is a compound similar to 2MIB, that is, in addition to 2MIB, isoborneol (hereinafter referred to as IMIB).
B), borneol, camphor,
It is a monoclonal antibody that does not substantially react with norborneol and norcamphor, and particularly has a measurement sensitivity of 2 MIB at a level of 5 ng / assay. The second aspect of the present invention is
A specific immune reaction with 2-methylisoborneol was made from hybridomas prepared by cell fusion of lymph cells and myeloma cells of an animal previously immunized with an antigen having 2-methylisoborneol or a similar compound as a hapten. The method for producing a monoclonal antibody is characterized in that a hybridoma producing the indicated monoclonal antibody is selected and the hybridoma is cultured. The third aspect of the present invention is the method for producing the above monoclonal antibody, wherein the 2MIB analog is IB. The fourth aspect of the present invention is a hybridoma producing the above-mentioned monoclonal antibody. The fifth aspect of the present invention is to specifically immunize 2MIB among hybridomas prepared by cell fusion of lymphocytes and myeloma cells of an animal previously immunized with an antigen having 2MIB or a similar compound as a hapten. The method for producing a hybridoma is characterized in that a hybridoma producing a monoclonal antibody showing a reaction is selected. A sixth aspect of the present invention is that the compound similar to 2MIB is IB
The method for producing the hybridoma is A seventh aspect of the present invention is a method for measuring 2-methylisoborneol, which comprises using the monoclonal antibody. This measuring method is suitable for measuring 2MIB in the environment, and by extension, for measuring odor and off taste, and is expected to be used particularly in the waterworks field.
【0009】なお、本発明でいう「免疫反応」とは、生
体の内外に係わらず、抗原またはハプテンと抗体との結
合を示す、広義な意味である。The term "immune reaction" as used in the present invention has a broad meaning indicating the binding between an antigen or a hapten and an antibody regardless of whether it is inside or outside the living body.
【0010】免疫用抗原の調製 前記のように低分子物質に対する抗体を作製する場合、
それ自身は免疫原性を持たないため、蛋白質などの高分
子と結合させて、その結合体を動物に免疫する。2MI
Bを認識する抗体を作製する場合にも、同様に2MIB
を蛋白質に結合させ、その結合体を免疫用抗原として用
いる。また2MIBより入手しやすいカンファーやイソ
ボルネオール(IB)などの類似化合物を用いても2M
IBを認識する抗体を得ることができる。カンファーを
用いる場合は、たとえばChungらの方法(J.Ag
ric.Food Chem.、38、410〜415
(1990))に従い免疫用抗原を作製できる。2MI
BやIBを用いる場合は、その水酸基に無水コハク酸又
は無水グルタル酸を反応させてカルボキシル基を導入
し、そのカルボキシル基を利用してカルボジイミド法あ
るいは酸無水法などにより蛋白質に結合させ、この結合
体を免疫用抗原とすることができる。前記蛋白質として
は特に限定はしないが、ウシ血清アルブミン(BS
A)、卵白アルブミン(OVA)、陣笠貝ヘモシアニン
(KLH)などを用いることができる。Preparation of Immunizing Antigen When producing an antibody against a low molecular weight substance as described above,
Since it has no immunogenicity by itself, it binds to macromolecules such as proteins and immunizes animals with the conjugate. 2 MI
Similarly, when producing an antibody that recognizes B, 2 MIB
Is bound to a protein and the conjugate is used as an immunizing antigen. In addition, even if a similar compound such as camphor or isoborneol (IB), which is more easily available than 2MIB, is used,
An antibody that recognizes IB can be obtained. When camphor is used, for example, the method of Chung et al. (J. Ag.
ric. Food Chem. , 38 , 410-415
(1990)), an immunizing antigen can be prepared. 2 MI
When B or IB is used, the hydroxyl group is reacted with succinic anhydride or glutaric anhydride to introduce a carboxyl group, and the carboxyl group is used to bind to a protein by a carbodiimide method or an acid anhydride method. The body can be the antigen for immunization. The protein is not particularly limited, but bovine serum albumin (BS
A), ovalbumin (OVA), Jinkasai hemocyanin (KLH) and the like can be used.
【0011】モノクローナル抗体製造法 モノクローナル抗体の製造法は、基本的にはKoehl
erとMilsteinらの方法(Nature、25
6、495、1975)やその変法(J.Immuno
l.Methods、39、285、1980)により
行うことができる。Monoclonal Antibody Production Method The monoclonal antibody production method is basically based on Koehl.
er and Milstein et al. (Nature, 25
6 , 495, 1975) and its variants (J. Immuno)
l. Methods, 39 , 285, 1980).
【0012】ハイブリドーマの作製 免疫される動物としてはマウス、ラット等があげられ、
接種方法は皮下、筋肉または腹腔内に投与される。免疫
は1〜4週間の間隔で3〜5回に分けて行うが、このと
き完全フロイントアジュバントや不完全フロイントアジ
ュバントと混和して投与することが好ましい。免疫され
た動物の脾臓あるいはリンパ節から得られた抗体産生細
胞は、ミエローマ細胞と細胞融合してハイブリドーマと
して単離する。ミエローマ細胞としては、マウス、ラッ
ト等由来のものが使用され、抗体産生細胞と同種由来で
あることが好ましい。Preparation of hybridoma Examples of animals to be immunized include mice and rats.
The method of inoculation is subcutaneous, intramuscular or intraperitoneal. Immunization is performed in 3 to 5 divided doses at an interval of 1 to 4 weeks, and it is preferable that the immunization be mixed with complete Freund's adjuvant or incomplete Freund's adjuvant for administration. Antibody-producing cells obtained from the spleen or lymph node of the immunized animal are fused with myeloma cells and isolated as hybridomas. As the myeloma cells, those derived from mice, rats, etc. are used, and preferably derived from the same species as the antibody-producing cells.
【0013】細胞融合時の前記抗体産生細胞とミエロー
マ細胞の混合比は、1〜10:1程度とし、ポリエチレ
ングリコール(PEG)またはセンダイウイルス(HV
J)などの融合促進剤を用いて融合させるが、操作上の
点から、30%〜60%のPEG(分子量1000〜8
000)溶液を用いることが好ましい。ハイブリドーマ
の選択は、通常HAT(ヒポキサンチン、アミノプテリ
ン、チミジン)と10〜20%牛胎児血清(FCS)を
含む動物細胞培養用培地(IMDM、DMEM、RPM
I1640、MEMなど)で培養することにより行われ
る。At the time of cell fusion, the mixing ratio of the antibody-producing cells and myeloma cells is about 1 to 10: 1, and polyethylene glycol (PEG) or Sendai virus (HV) is used.
J) and the like are used for fusion, but from the viewpoint of operation, 30% to 60% PEG (molecular weight 1000 to 8) is used.
000) solution is preferably used. Hybridomas are usually selected by a medium for animal cell culture (IMDM, DMEM, RPM) containing HAT (hypoxanthine, aminopterin, thymidine) and 10 to 20% fetal calf serum (FCS).
I1640, MEM, etc.).
【0014】ハイブリドーマの増殖を確認し、その培養
上清中に目的とする抗体が産生されているか否かを測定
する。測定方法としては、RIA(ラジオイムノアッセ
イ)法、ELISA(酵素免疫測定)法、FIA(蛍光
イムノアッセイ)法、プラーク測定法、凝集反応法等を
用いることができるが、以下に示すようなELISA法
を用いることが望ましい。The growth of the hybridoma is confirmed, and it is determined whether or not the desired antibody is produced in the culture supernatant. As the measuring method, RIA (radioimmunoassay) method, ELISA (enzyme immunoassay) method, FIA (fluorescent immunoassay) method, plaque measuring method, agglutination reaction method and the like can be used, and the following ELISA method is used. It is desirable to use.
【0015】ELISA法によるスクリーニング 免疫抗原と同様の操作で調製した蛋白質結合体をELI
SAプレートの各ウェルの表面に固定化する。次ぎに非
特異的吸着を防止する目的で、BSA、OVA、KLH
あるいはゼラチン、スキムミルクなどを各ウェルに固定
化する。この各ウェルにハイブリドーマ培養上清液を添
加し一定時間放置し免疫反応を行わせる。PBS(リン
酸緩衝生理食塩水)などを洗浄液として各ウェルを洗浄
する。この洗浄液には界面活性剤を添加することが好ま
しい。酵素標議2次抗体を添加し一定時間放置する。標
識酵素としては、β−ガラクトシダーゼ、アルカリホス
ファターゼ、ペルオキシダーゼなどを用いることができ
る。同じ洗浄液で各ウェルを洗浄後、使用した標識酵素
の基質溶液を添加し酵素反応を行わせる。添加したハイ
ブリドーマ培養上清中に目的とする抗体が存在する場
合、酵素反応が進行し基質溶液の色が変化する。Screening by ELISA The protein conjugate prepared by the same procedure as the immunizing antigen was subjected to ELI.
Immobilize on the surface of each well of the SA plate. Next, for the purpose of preventing non-specific adsorption, BSA, OVA, KLH
Alternatively, gelatin, skim milk, etc. are immobilized in each well. The hybridoma culture supernatant is added to each well and left for a certain period of time to carry out an immune reaction. Each well is washed with PBS (phosphate buffered saline) or the like as a washing solution. It is preferable to add a surfactant to this cleaning liquid. Add the enzyme-labeled secondary antibody and leave it for a certain period of time. As the labeling enzyme, β-galactosidase, alkaline phosphatase, peroxidase and the like can be used. After washing each well with the same washing solution, the substrate solution of the labeling enzyme used is added to carry out the enzyme reaction. When the desired antibody is present in the added hybridoma culture supernatant, the enzymatic reaction proceeds and the color of the substrate solution changes.
【0016】ハイブリドーマのクローニング 前記の方法で目的とする抗体を産生するウェルを確認し
たなら、クローニングを行いシングルクローンを得る。
クローニング法としては、培養プレートの1ウェルあた
りに1個のコロニーが形成するようにハイブリドーマ細
胞を希釈して培養する限界希釈法などを用いればよい。
限界希釈法によるクローニングにはコロニー形成率を高
めるため支持細胞を用いるか、インターロイキン6(I
L6)などの細胞増殖因子を添加することが望ましい。
このようにして得られたハイブリドーマ細胞は、工業技
術院生命工学工業技術研究所に受託番号〔FERM P
−14789〕として寄託されている。Cloning of hybridoma After confirming the well producing the desired antibody by the above method, cloning is performed to obtain a single clone.
As a cloning method, a limiting dilution method or the like in which hybridoma cells are diluted and cultured so that one colony is formed per well of a culture plate may be used.
For cloning by the limiting dilution method, use feeder cells to increase the colony formation rate, or use interleukin 6 (I
It is desirable to add cell growth factors such as L6).
The hybridoma cells obtained in this way are deposited with the deposit number [FERM P
-14789].
【0017】このようにして得られた単一なハイブリド
ーマは、フラスコや細胞培養装置を用いて大量培養を行
うか、動物の腹腔内で培養することにより、モノクロー
ナル抗体を得ることができる。フラスコ内で培養を行う
場合は、0〜20%のFCSを含む細胞培養用培地(I
MDM、DMEM、RPMI1640、MEMなど)を
用いて行うことができる。動物の腹腔内で培養する場合
は、細胞融合に使用したミエローマ細胞の由来となった
動物と同種、同系統の動物を使用することが好ましく、
あらかじめプリスタン等を投与してからハイブリドーマ
を移植する。1〜2週間後腹腔内にミエローマ細胞が増
殖し、モノクローナル抗体を含む腹水を得ることができ
る。こうして得られた細胞培養上清や腹水からモノクロ
ーナル抗体を精製するには、塩析、ゲル濾過、イオン交
換クロマトグラフィー、アフィニティクロマトグラフィ
ーなどの手段により行うことができる。The single hybridoma thus obtained can be subjected to large-scale culture using a flask or a cell culture device, or can be cultured in the abdominal cavity of an animal to obtain a monoclonal antibody. When culturing in a flask, a cell culture medium containing 0 to 20% FCS (I
(MDM, DMEM, RPMI1640, MEM, etc.). When cultured in the abdominal cavity of an animal, it is preferable to use an animal of the same species and strain as the origin of the myeloma cells used for cell fusion,
The hybridoma is transplanted after pristane or the like is administered in advance. After 1-2 weeks, myeloma cells proliferate in the abdominal cavity, and ascites containing the monoclonal antibody can be obtained. The monoclonal antibody can be purified from the thus obtained cell culture supernatant and ascites by means such as salting out, gel filtration, ion exchange chromatography, affinity chromatography and the like.
【0018】このようにして得られた抗2MIBモノク
ローナル抗体を用いる免疫測定法に1り、河川や湖沼な
ど環境水中の2MIBの定性および定量が迅速、簡単に
行うことができる。免疫測定法としては、RIA、EL
ISA、FIAなど既知の方法を用いることができる。According to the immunoassay method using the anti-2MIB monoclonal antibody thus obtained, qualitative and quantitative determination of 2MIB in environmental water such as rivers and lakes can be performed quickly and easily. Immunoassay methods include RIA and EL
Known methods such as ISA and FIA can be used.
【0019】[0019]
【実施例】以下、本発明を実施例により更に詳細に説明
するが、本発明はこれらの実施例に限定されるものでは
ない。 実施例1 2MIBを認識する抗体の作製 1.IBのカルボキシル基導入法 予め脱水処理した2mlのピリジンに50mgのIBを
加え、溶解後700mgの無水グルタル酸(HG)を加
え、密閉して70℃、20時間反応させた。反応後等量
の蒸留水を加えて撹拌した後、遠心分離(15000r
pm、5分間)を行い、上層の水相部分を除去、さらに
20mlのジクロロメタンにより抽出を行った。そして
ジクロロメタン相を蒸留水により9回洗浄し、無水硫酸
ナトリウムを用いて脱水した後、窒素ガス気流下で乾固
した。この残留物をIB−HGとしてキャリア蛋白質へ
の結合に使用した。EXAMPLES The present invention will now be described in more detail with reference to examples, but the present invention is not limited to these examples. Example 1 Preparation of antibody recognizing 2MIB 1. Method for Introducing Carboxyl Group of IB 50 mg of IB was added to 2 ml of pyridine that had been dehydrated in advance, 700 mg of glutaric anhydride (HG) was added after dissolution, and the mixture was sealed and reacted at 70 ° C. for 20 hours. After the reaction, add an equal amount of distilled water and stir, then centrifuge (15000 r
pm, 5 minutes) to remove the upper aqueous phase and extract with 20 ml of dichloromethane. The dichloromethane phase was washed 9 times with distilled water, dehydrated with anhydrous sodium sulfate, and then dried under a nitrogen gas stream. This residue was used as IB-HG for binding to carrier protein.
【0020】2.IB−HG−蛋白質結合体の調製法 0.9%塩化ナトリウムを含む10mMリン酸ナトリウ
ム緩衝液(pH7.0)に20mgの牛血清アルブミン
(BSA)を溶解し、40mgの1−エチル−3−(3
−ジメチルアミノプロピル)−カルボジイミド ハイド
ロクロライドを加えた。2.4mgのIB−HGを10
0μlのジメチルホルムアミドに溶解し、滴下させなが
ら蛋白質溶液に混合した。このときのBSAとIB−H
Gとのモル混合比は1:30であった。12時間、室温
で撹拌した後、0.9%塩化ナトリウム溶液に対して3
日間透析した。同様の操作で卵白アルブミン(OVA)
とIB−HGとではモル混合比が1:20に、ヘモシア
ニン(KLH)とIB−HGとでは1:200になるよ
うにIB−HGを添加した。調整した結合体は透析終了
後、遠心分離(12000rpm、30分間)してその
上清を小分けして使用時まで4℃に保存した。2. Method for Preparing IB-HG-Protein Conjugate 20 mg bovine serum albumin (BSA) was dissolved in 10 mM sodium phosphate buffer (pH 7.0) containing 0.9% sodium chloride, and 40 mg 1-ethyl-3- (3
-Dimethylaminopropyl) -carbodiimide hydrochloride was added. 2.4 mg of IB-HG 10
It was dissolved in 0 μl of dimethylformamide, and was added dropwise to the protein solution. BSA and IB-H at this time
The molar mixing ratio with G was 1:30. After stirring for 12 hours at room temperature, 3% against 0.9% sodium chloride solution
He dialyzed for a day. Ovalbumin (OVA) by the same operation
And IB-HG were added so that the molar mixing ratio was 1:20, and hemocyanin (KLH) and IB-HG were 1: 200. The prepared conjugate was centrifuged (12000 rpm, 30 minutes) after dialysis, and the supernatant was divided into small portions and stored at 4 ° C until use.
【0021】3.免 疫 初回免疫は抗原を生理食塩水で希釈した後フロイントの
完全アジュバントを1:1で混合しエマルジョン化させ
た後、Balb/cマウス(雌、8週齢)1匹あたり5
0μg蛋白質となるように2ケ所に分けて背部皮下に投
与した。追加免疫は1週間後、今度はフロイント不完全
アジュバントを用いて同様に投与した。さらにその2週
間後、生理食塩水で希釈した抗原液をマウスあたり50
μgとなるように尾静脈内に投与した。3. Immunization For the primary immunization, the antigen was diluted with physiological saline, Freund's complete adjuvant was mixed at 1: 1 to emulsify, and then Balb / c mice (female, 8 weeks old) were treated with 5 per mouse.
It was subcutaneously administered to the back at two sites so that the amount of protein became 0 μg. The booster was administered one week later, this time using Freund's incomplete adjuvant. Two weeks later, 50 ml of the antigen solution diluted with physiological saline was added to each mouse.
It was administered into the tail vein so that the dose became μg.
【0022】4.細胞融合 最終免疫の3日後、マウスの脾臓を無菌的に摘出し、M
EM培地に脾リンパ細胞を分散させた。リンパ細胞浮遊
液は遠心分離(1600rpm、5分間)して回収し、
MEM培地に再分散させることにより3回洗浄した。得
られた1×108個の脾リンパ細胞は2×107個のミエ
ローマ細胞(SP2/0−Ag14株)と混合し、遠心
分離(1600rpm、5分間)後上清を完全に吸引除
去し、遠心チューブの底をたたいて沈殿物をほぐした。
そして1mlの50%PEG4000溶液を1分間かけ
て滴下した。そのままさらに1分間振とう撹拌した後、
2mlのMEMを2分間かけて滴下した。さらに7ml
のMEMを3分間かけて添加した。遠心分離(800r
pm、6分間)後、上清を吸引除去し、沈殿物をほぐし
た後、HAT培地(1×10-4Mヒポキサンチン、4×
10-7Mアザグアニン、1.6×10-5Mチミジン、2
0%FCSを含むDMEM培地)を30ml加えて再懸
濁した。細胞浮遊液は、その全量を96ウェルプレート
の各ウェルに0.1mlずつ分注し、CO2インキュベ
ーター内で培養した。細胞融合の翌日にHAT培地を2
滴ずつ添加した。さらに融合後3日目、6日目、8日
目、10日目、12日目に半量ずつ新しい培地と交換し
た。その結果、ほとんどすべてのウェルにハイブリドー
マの増殖が認められた。14日目、ELISA法により
各ウェルの培養上清中の抗体力価を測定することにより
スクリーニングを行った。4. Cell fusion 3 days after the final immunization, the spleen of the mouse was aseptically removed and
Splenic lymphocytes were dispersed in EM medium. The lymphocyte suspension was collected by centrifugation (1600 rpm, 5 minutes),
It was washed three times by redispersion in MEM medium. The obtained 1 × 10 8 splenic lymphocytes were mixed with 2 × 10 7 myeloma cells (SP2 / 0-Ag14 strain), centrifuged (1600 rpm, 5 minutes), and the supernatant was completely removed by suction. The bottom of the centrifuge tube was tapped to loosen the precipitate.
Then, 1 ml of 50% PEG4000 solution was added dropwise over 1 minute. After shaking and stirring for another minute as it is,
2 ml of MEM was added dropwise over 2 minutes. 7 ml more
MEM was added over 3 minutes. Centrifuge (800r
pm, 6 minutes), the supernatant was removed by suction, the precipitate was loosened, and then HAT medium (1 × 10 −4 M hypoxanthine, 4 ×) was used.
10 −7 M azaguanine, 1.6 × 10 −5 M thymidine, 2
30 ml of DMEM medium containing 0% FCS was added and resuspended. The total amount of the cell suspension was dispensed into each well of a 96-well plate in an amount of 0.1 ml and cultured in a CO 2 incubator. The day after cell fusion, HAT medium was added to 2
It was added drop-wise. Further, on the third day, the sixth day, the eighth day, the tenth day, and the twelfth day after the fusion, half the amount of the medium was replaced with a new medium. As a result, proliferation of hybridoma was observed in almost all wells. On day 14, screening was performed by measuring the antibody titer in the culture supernatant of each well by the ELISA method.
【0023】5.抗体活性の測定法 抗体力価はすべてELISA法によって行った。まず9
6ウェルEIAプレートの各ウェルにPBSで希釈した
IB−HG−OVA(0.1μg/mlを100μl加
え、4℃で一晩放置してIB−HG−OVAをウェル表
面に固定化した。非結合物を除去するため、0.05%
ツイーン20を含むPBS(PBS−Tween)で4
回洗浄した。125μlのブロッキング液(0.1%O
VA、0.01%アジ化ナトリウム含有PBS)を加
え、4℃で一晩放置した。使用前にPBS−Tween
で洗浄し、PBS−Tweenで希釈した培養上清希釈
液を100μl添加し、1時間、室温に放置して抗原抗
体反応を進行させた。放置後未反応物を除去するため、
PBS−Tweenで4回洗浄し、アルカリホスファタ
ーゼ(ALP)標識ヤギ抗マウス免疫グロブリンG+M
抗体をPBS−Tweenで5000倍に希釈し、l0
0μl添加した。さらに1時間室温に放置した後、PB
S−Tweenで4回洗浄して100μlのALP基質
溶液を添加した。ALP基質溶液は、使用直前にp−ニ
トロフェニルリン酸二ナトリウムを1mg/mlになる
ようにジエタノールアミン緩衝液に溶解した。そして3
0分間、室温に放置した後、マイクロプレートリーダー
により405nmの吸光度を測定した。その結果、34
ウェルの培養上清がIB−HG−OVAと免疫反応を示
した。5. Method for measuring antibody activity All antibody titers were determined by the ELISA method. First 9
100 μl of IB-HG-OVA (0.1 μg / ml) diluted with PBS was added to each well of a 6-well EIA plate and left overnight at 4 ° C. to immobilize IB-HG-OVA on the well surface. 0.05% to remove things
4 with PBS containing Tween 20 (PBS-Tween)
Washed twice. 125 μl of blocking solution (0.1% O
VA, PBS containing 0.01% sodium azide) was added, and the mixture was left at 4 ° C. overnight. PBS-Tween before use
100 μl of a diluted culture supernatant diluted with PBS-Tween was added and left at room temperature for 1 hour to allow the antigen-antibody reaction to proceed. To remove unreacted materials after leaving,
After washing 4 times with PBS-Tween, alkaline phosphatase (ALP) -labeled goat anti-mouse immunoglobulin G + M
Dilute antibody 5000 times with PBS-Tween and
0 μl was added. After leaving at room temperature for another hour, PB
After washing 4 times with S-Tween, 100 μl of ALP substrate solution was added. Immediately before use, the ALP substrate solution was prepared by dissolving disodium p-nitrophenylphosphate in diethanolamine buffer at a concentration of 1 mg / ml. And 3
After leaving it at room temperature for 0 minutes, the absorbance at 405 nm was measured by a microplate reader. As a result, 34
The culture supernatant of the well showed an immunoreactivity with IB-HG-OVA.
【0024】さらに抗2MIB抗体産生ハイブリドーマ
を同定するために、競合ELISA法を行った。競合E
LISA法は、前記ELISA法の培養上清希釈液と固
相抗原との反応の際に遊離2MIBを共存させることに
より行った。ここで抗2MIB抗体は遊離2MIBと固
定化抗原に対して競合的に反応するため、固定化抗原に
対する阻害反応が認められるウェルには抗2MIB抗体
産生ハイブリドーマが存在することが確認できる。具体
的な操作方法としては50μlの培養上清希釈液と同時
に、100μl/mlの2MIB溶液を50μlを添加
する以外は前記ELISA法と同様の操作を行った。そ
の結果、表1からわかるように、IB−HG−OVAと
免疫反応を示す32の陽性ウェルのうち9ウェルの培養
上清で遊離2MIBによる阻害反応が顕著であるウェ
ル、つまり、阻害率が高い即ち抗2MIB抗体を多く含
むウェルを3個確認した。Further, a competitive ELISA method was carried out to identify hybridomas producing anti-2MIB antibody. Conflict E
The LISA method was performed by allowing free 2MIB to coexist during the reaction between the diluted culture supernatant of the ELISA method and the solid phase antigen. Here, since the anti-2MIB antibody competitively reacts with the free 2MIB and the immobilized antigen, it can be confirmed that the anti-2MIB antibody-producing hybridoma is present in the well where the inhibitory reaction against the immobilized antigen is observed. As a specific operation method, the same operation as in the ELISA method was performed except that 50 μl of 100 μl / ml 2MIB solution was added simultaneously with 50 μl of the culture supernatant diluted solution. As a result, as can be seen from Table 1, of the 32 positive wells showing an immunoreactivity with IB-HG-OVA, the wells in which the inhibition reaction by free 2MIB was remarkable in the culture supernatant of 9 wells, that is, the inhibition rate was high. That is, three wells containing a large amount of anti-2MIB antibody were confirmed.
【0025】[0025]
【表1】 [Table 1]
【0026】6.クローニング このようにして得られた3株の抗2MIB抗体産生ハイ
ブリドーマは、ただちにクローニングした。クローニン
グは、限界希釈法により行った。クローニング用培地と
して1回目はHT培地(アミノプテリン不含HAT培
地)、2回目以降は20%FCS−DMEM培地を使用
し、2U/mlのIL6を添加した。6. Cloning The 3 strains of anti-2MIB antibody-producing hybridomas thus obtained were immediately cloned. Cloning was performed by the limiting dilution method. As a medium for cloning, HT medium (HAT medium without aminopterin) was used for the first time, 20% FCS-DMEM medium was used for the second time and thereafter, and 2 U / ml of IL6 was added.
【0027】操作はハイブリドーマ細胞濃度が10個/
mlになるよう前記培地で希釈して、その希釈液0.1
mlを96ウェルマイクロプレートの各ウェルに分注し
た。5日間培養後に同培地を2滴ずつ滴下し、10日か
ら14日間培養を行った。そしてコロニー形成を確認
後、上清の抗体活性を前記の方法で測定した。陽性ウェ
ルはクローニングを3回行うことにより純化し、その結
果、2MIBに対して特異的に免疫反応をするモノクロ
ーナル抗体(以下、単に抗2MIBモノクローナル抗体
または抗2MIB抗体ともいう)産生ハイブリドーマ2
MIB−1、2MIB−7、2MIB−8を得ることが
できた。これらの抗体力価を測定した結果を表2に示
す。The operation was carried out at a hybridoma cell concentration of 10 cells /
Dilute to 0.1 ml with the above medium and add 0.1
ml was dispensed into each well of a 96-well microplate. After culturing for 5 days, two drops of the same medium were added dropwise and culturing was carried out for 10 to 14 days. After confirming colony formation, the antibody activity of the supernatant was measured by the above method. Positive wells were purified by cloning three times, and as a result, a monoclonal antibody (hereinafter also simply referred to as anti-2MIB monoclonal antibody or anti-2MIB antibody) -producing hybridoma 2 that specifically immunoreacts with 2MIB was produced.
MIB-1, 2MIB-7, and 2MIB-8 were able to be obtained. The results of measuring these antibody titers are shown in Table 2.
【0028】[0028]
【表2】 [Table 2]
【0029】この表より特に抗体力価の高いものを選定
し寄託した。この抗2MIB抗体産生ハイブリドーマ2
MIB−1(以下、単にハイブリドーマ2MIB−1ま
たは2MIB−1等とも称す)は、工業技術院生命工学
工業技術研究所に1995年2月24日付けで受託さ
れ、受託番号〔FERM P−14789〕を得てい
る。From this table, those with particularly high antibody titers were selected and deposited. This anti-2MIB antibody producing hybridoma 2
MIB-1 (hereinafter, also simply referred to as hybridoma 2MIB-1 or 2MIB-1 etc.) was entrusted to the Institute of Biotechnology, Institute of Industrial Science and Technology as of February 24, 1995, and the accession number [FERM P-14789]. Is getting
【0030】7.モノクローナル抗体の産生 このようにして得られたハイブリドーマ2MIB−1株
について、20%FCS−DMEMを用いて培養した。
培養は、細胞の80%以上が死滅するまで行い、その培
養上清を遠心分離(3000rpm、15分)して回収
した。回収した培養上清は、0.02Mリン酸緩衝液
(pH7.0)(PBS)で希釈した後、プロテインG
カラムを用いたアフィニティクロマトグラフィーにより
抗2MIBモノクローナル抗体を精製した。なお、該ク
ロマトグラフィーの条件は、抗体希釈液をプロテインG
セファロースカラムに通し、0.02Mリン酸緩衝液
(pH7.0)により抗体以外の成分を洗浄除去した
後、0.1Mグリシン塩酸緩衝液(pH2.7)により
抗体を溶出した。溶出液は直ちに中和した後、PBSで
透析した。7. Production of Monoclonal Antibody The hybridoma 2MIB-1 strain thus obtained was cultured using 20% FCS-DMEM.
The culture was performed until 80% or more of the cells were dead, and the culture supernatant was collected by centrifugation (3000 rpm, 15 minutes). The recovered culture supernatant was diluted with 0.02 M phosphate buffer (pH 7.0) (PBS) and then diluted with protein G.
The anti-2MIB monoclonal antibody was purified by affinity chromatography using a column. The chromatography conditions are as follows:
After passing through a Sepharose column to wash and remove components other than the antibody with 0.02 M phosphate buffer (pH 7.0), the antibody was eluted with 0.1 M glycine-hydrochloric acid buffer (pH 2.7). The eluate was immediately neutralized and then dialyzed against PBS.
【0031】また予め0.5ml/匹のプリスタンを投
与したBalb/cマウス(雌、6週齢)の腹腔内へ1
×107個のハイブリドーマ2MIB−1を移植し、1
〜2週間後抗2MIBモノクローナル抗体を含む腹水を
採取した。腹水はPBSで5倍に希釈した後、硫酸アン
モニウムを40%濃度となるように添加し、遠心分離
(12000rpm、20分)により沈殿物を回収し
た。沈殿物は、PBSに再溶解してPBSに対して透析
した。透析後、プロテインGカラムを用いたアフィニテ
ィクロマトグラフィーによりモノクローナル抗体を精製
した。Intraperitoneally into Balb / c mice (female, 6 weeks old) pre-administered 0.5 ml / mouse of pristane 1
X10 7 hybridoma 2MIB-1 were transplanted and 1
After 2 weeks, ascites fluid containing anti-2MIB monoclonal antibody was collected. The ascites was diluted 5 times with PBS, ammonium sulfate was added to have a concentration of 40%, and the precipitate was collected by centrifugation (12000 rpm, 20 minutes). The precipitate was redissolved in PBS and dialyzed against PBS. After dialysis, the monoclonal antibody was purified by affinity chromatography using a protein G column.
【0032】8.モノクローナル抗体の特性 Mouse Monoclonal Antibody
IsotypingKit(アマシャム社)を用いて
モノクローナル抗体のクラス、サブクラスを決定した。
その結果、得られた抗2MIBモノクローナル抗体は、
IgG1(κ)に属する抗体であった。抗2MIBモノ
クローナル抗体の特異性を調べるため、抗体とIB−H
G−OVAとの反応が遊離2MIBやその類似化合物に
よって阻害を受けるか測定した。その結果、抗2MIB
モノクローナル抗体を用いた2MIBの検出感度は、5
ng/アッセイであった(図1参照)。また抗2MIB
モノクローナル抗体は、2MIB、IB、ボルネオール
及びカンファーに対して同等に反応し、5μg/アッセ
イ以下のノルボルネオール、ノルカンファーとは反応し
なかった。また他の上水異臭味物質であるジオスミンと
も同濃度において反応しなかった。8. Characteristics of Monoclonal Antibody Mouse Monoclonal Antibody
The class and subclass of the monoclonal antibody were determined using Isotyping Kit (Amersham).
As a result, the obtained anti-2MIB monoclonal antibody was
It was an antibody belonging to IgG 1 (κ). In order to investigate the specificity of the anti-2MIB monoclonal antibody, the antibody and IB-H
It was determined whether the reaction with G-OVA was inhibited by free 2MIB or its analogues. As a result, anti-2MIB
The detection sensitivity of 2MIB using a monoclonal antibody is 5
ng / assay (see Figure 1). Anti-2 MIB
Monoclonal antibodies reacted equally to 2MIB, IB, borneol and camphor and did not react with norborneol, norcamphor below 5 μg / assay. In addition, it did not react with diosmin, which is another off-taste substance in tap water, at the same concentration.
【0033】9.水中の2MIB量の測定 (1)予め100ng/mlのIB−OVAを固定化し
たEIAプレートに0.05mlの抗体希釈液(20%
メタノールを含む2倍濃度のPBS−Tweenで希
釈)を添加した。そこに2MIBを産生する放線菌の培
養液を0.2μmフィルターで濾過し、その濾過液0.
05mlを添加した。また2MIBを産生する放線菌を
含まない培養液を同様に濾過したものをコントロールと
し、既知濃度の2MIBを含む標準液とともに使用し
た。よく攪拌して2時間室温で反応させた。以下実施例
1の5の抗体活性の測定法に記載した方法に準じた。そ
の結果、本培養液中には0.16mg/リットルの2M
IBが存在してることを確認した。9. Measurement of 2MIB amount in water (1) 0.05 ml of antibody diluent (20%) on an EIA plate on which 100 ng / ml IB-OVA was immobilized in advance.
2 times concentrated PBS-Tween containing methanol) was added. The culture solution of actinomycetes which produces 2MIB was filtered through a 0.2 μm filter, and the filtrate was diluted with 0.
05 ml was added. A culture solution containing no actinomycetes that produces 2MIB was similarly filtered and used as a control together with a standard solution containing a known concentration of 2MIB. The mixture was well stirred and reacted at room temperature for 2 hours. The method described in the method for measuring antibody activity in 5 of Example 1 was followed. As a result, 0.16 mg / liter of 2M was added to the main culture solution.
It was confirmed that IB was present.
【0034】この測定方法では、20個のサンプルを前
処理して測定するのに約3時間要した。これに対して、
従来のガスクロマトグラフィー法では、1検体あたり約
30分程度必要であり、多量のサンプルを測定するには
時間を要する。In this measuring method, it took about 3 hours to pretreat and measure 20 samples. On the contrary,
In the conventional gas chromatography method, about 30 minutes are required for each sample, and it takes time to measure a large amount of samples.
【0035】(2)河川水5リットルを固相抽出用ボン
ドエルートC18カラム(ジーエルサイエンス社)に2
0ml/分で加圧注入した。6mlのジクロロメタンを
加えて2MIBを溶出させ、無水硫酸ナトリウムで脱水
した。N2ガス気流下にて再濃縮し、さらにメタノール
と置換し、全量を0.1mlとした。この濃縮液20μ
lを80μlの抗体希釈液(PBS−Tweenで希
釈)を含むIB−OVA固定化EIAプレートに分注
し、室温で反応を行った。以下実施例1の5の抗体活性
の測定法に記載した方法に準じた。その結果、本湖水中
には10ng/リットルの2MIBが存在していること
を確認した。(2) 2 liters of river water was applied to a Bond Elute C18 column (GL Sciences) for solid phase extraction.
Pressure injection was performed at 0 ml / min. 2 ml of MIB was eluted by adding 6 ml of dichloromethane and dehydrated with anhydrous sodium sulfate. It was re-concentrated in a stream of N 2 gas and replaced with methanol to make the total volume 0.1 ml. This concentrate 20μ
1 was dispensed on an IB-OVA-immobilized EIA plate containing 80 μl of an antibody diluent (diluted with PBS-Tween), and the reaction was carried out at room temperature. The method described in the method for measuring antibody activity in 5 of Example 1 was followed. As a result, it was confirmed that 10 ng / liter of 2MIB was present in the main lake water.
【0036】低濃度のサンプルの場合、本測定方法は、
前処理に約6時間、測定に約3時間要した。これは検体
数が増えても変わらない。In the case of a low concentration sample, this measuring method is
The pretreatment required about 6 hours and the measurement required about 3 hours. This does not change even if the number of specimens increases.
【0037】[0037]
【発明の効果】本発明の新規モノクローナル抗体は、2
MIB類に対して特異的に反応するものであり、そのた
め本モノクローナル抗体を用いることにより、水中の2
MIB濃度を特異的に、ポリクローナル抗体を用いたE
LISA法と比べて高感度、迅速簡単に測定することが
可能となった。また本測定には、簡易吸光度計さえあれ
ばよく、そのため屋外の現場などでも実施可能である。
そのためサンプルを分析室に輸送する必要がなく、素早
い対応ができる。特に従来のポリクローナル抗体を用い
たELISA法との感度差は明確である。更に現場での
測定を可能としたのでより柔軟で、緻密な測定が可能に
なった。また本モノクローナル抗体は、新規なハイブリ
ドーマにより産生されるものであるが、このハイブリド
ーマは液体窒素中で半永久的に保存可能であり、解凍し
て培養することにより、いつでも同一の特性を有する単
一の抗体を必要なだけ得ることができる。The novel monoclonal antibody of the present invention is 2
Since it reacts specifically with MIBs, the use of this monoclonal antibody enables the
E with a polyclonal antibody specifically for the MIB concentration
Compared to the LISA method, it has become possible to measure with high sensitivity and quickly and easily. In addition, a simple absorbance meter is sufficient for this measurement, and therefore it can be carried out at the outdoor site.
Therefore, there is no need to transport the sample to the analysis room, and quick response is possible. Especially, the difference in sensitivity from the conventional ELISA method using a polyclonal antibody is clear. Furthermore, since it enables on-site measurement, it is more flexible and enables precise measurement. The present monoclonal antibody is produced by a novel hybridoma, which can be stored semipermanently in liquid nitrogen and can be thawed and cultured to obtain a single antibody having the same characteristics at any time. You can get as many antibodies as you need.
【図1】2MIB.1モノクローナル抗体の2MIB及
び2MIB類似化合物との交叉反応性を示すグラフ。FIG. 1 2 MIB. 3 is a graph showing the cross-reactivity of 1 monoclonal antibody with 2MIB and 2MIB-like compounds.
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.6 識別記号 庁内整理番号 FI 技術表示箇所 //(C12P 21/08 C12R 1:91) (C12N 5/10 C12R 1:91) (C12N 15/02 C12R 1:91) ─────────────────────────────────────────────────── ─── Continuation of the front page (51) Int.Cl. 6 Identification number Office reference number FI technical display location // (C12P 21/08 C12R 1:91) (C12N 5/10 C12R 1:91) (C12N 15 / 02 C12R 1:91)
Claims (7)
異的に免疫反応をするモノクローナル抗体。1. A monoclonal antibody which specifically immunoreacts with 2-methylisoborneol.
類似化合物をハプテンとした抗原であらかじめ免疫され
た動物のリンパ細胞とミエローマ細胞との細胞融合によ
り作製されたハイブリドーマのなかから2−メチルイソ
ボルネオールと特異的に免疫反応を示すモノクローナル
抗体を産生するハイブリドーマを選択し、該ハイブリド
ーマを培養することを特徴とする請求項1記載のモノク
ローナル抗体の製造方法。2. A hybridoma produced by cell fusion of myeloma cells and lymph cells of an animal previously immunized with an antigen having 2-methylisoborneol or a similar compound as a hapten, and specific to 2-methylisoborneol. 2. The method for producing a monoclonal antibody according to claim 1, wherein a hybridoma producing a monoclonal antibody that shows an immunological reaction is selected and the hybridoma is cultured.
がイソボルネオールであることを特徴とする請求項2記
載のモノクローナル抗体の製造方法。3. The method for producing a monoclonal antibody according to claim 2, wherein the 2-methylisoborneol analogue is isoborneol.
生するハイブリドーマ。4. A hybridoma producing the monoclonal antibody according to claim 1.
類似化合物をハプテンとした抗原であらかじめ免疫され
た動物のリンパ細胞とミエローマ細胞との細胞融合によ
り作製されたハイブリドーマのなかから、2−メチルイ
ソボルネオールと特異的に免疫反応を示すモノクローナ
ル抗体を産生するハイブリドーマを選択することを特徴
とする請求項4記載のハイブリドーマの作製法。5. Among the hybridomas produced by cell fusion of myeloma cells and lymph cells of an animal previously immunized with an antigen having 2-methylisoborneol or a similar compound as a hapten, 2-methylisoborneol and The method for producing a hybridoma according to claim 4, wherein a hybridoma that produces a monoclonal antibody that specifically shows an immune reaction is selected.
がイソボルネオールであることを特徴とする請求項5記
載のハイブリドーマの作製法。6. The method for producing a hybridoma according to claim 5, wherein the 2-methylisoborneol analog compound is isoborneol.
いることを特徴とする2−メチルイソボルネオールの測
定方法。7. A method for measuring 2-methylisoborneol, which comprises using the monoclonal antibody according to claim 1.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP7078364A JPH08242883A (en) | 1995-03-10 | 1995-03-10 | Monoclonal antibody against 2-mthylisoborneol, its production and measurement of 2-methylisoborneol with the same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP7078364A JPH08242883A (en) | 1995-03-10 | 1995-03-10 | Monoclonal antibody against 2-mthylisoborneol, its production and measurement of 2-methylisoborneol with the same |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH08242883A true JPH08242883A (en) | 1996-09-24 |
Family
ID=13659956
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP7078364A Pending JPH08242883A (en) | 1995-03-10 | 1995-03-10 | Monoclonal antibody against 2-mthylisoborneol, its production and measurement of 2-methylisoborneol with the same |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH08242883A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6444433B1 (en) * | 2000-01-24 | 2002-09-03 | Board Of Supervisors Of Louisiana State University And Agriculture And Mechanical College | Detection of 2-methylisoborneol by monoclonal antibody production |
CN112358549A (en) * | 2020-09-28 | 2021-02-12 | 苏州科铭生物技术有限公司 | Preparation of dimethyl isotrichum monoclonal antibody and enzyme-linked immunosorbent assay method thereof |
-
1995
- 1995-03-10 JP JP7078364A patent/JPH08242883A/en active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6444433B1 (en) * | 2000-01-24 | 2002-09-03 | Board Of Supervisors Of Louisiana State University And Agriculture And Mechanical College | Detection of 2-methylisoborneol by monoclonal antibody production |
CN112358549A (en) * | 2020-09-28 | 2021-02-12 | 苏州科铭生物技术有限公司 | Preparation of dimethyl isotrichum monoclonal antibody and enzyme-linked immunosorbent assay method thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5767247A (en) | Anti-annexin-V monoclonal antibodies, and preparation and use thereof | |
US5248593A (en) | Process and reagent for the determination of the luteinizing hormone and monoclonal antibodies suitable thereof | |
US6818408B2 (en) | Monoclonal antibody recognizing phosphatidylinositol-3,4,5-triphosphate | |
CA1296660C (en) | Monoclonal antibody against a ras oncogene p21 related dodecapeptide | |
JPH09176199A (en) | Anti-factor Xa / tissue factor pathway inhibitor complex monoclonal antibody and use thereof | |
JPH08242883A (en) | Monoclonal antibody against 2-mthylisoborneol, its production and measurement of 2-methylisoborneol with the same | |
EP0401370A1 (en) | Enzyme immunoassay according to sandwich method of human iv-type collagen | |
US5650324A (en) | Inhibitor and anti-inhibitor monoclonal antibodies specific for horseradish peroxidase | |
JP4044648B2 (en) | Monoclonal antibody for immunological analysis of detergent or its degradation product and use thereof | |
US5264556A (en) | Monoclonal antibodies for measuring okadaic acid | |
JPH0789998A (en) | Anti-microcystin monoclonal antibody and hybridoma producing the same | |
Kashanian et al. | Preparation and characterization of monoclonal antibody against digoxin | |
JPH0677017B2 (en) | A method for the immunoassay of human dehydrogenase type IV collagen | |
JP4037933B2 (en) | Anti-human calcitonin monoclonal antibody | |
CA2355893C (en) | Antiuracil monoclonal antibody | |
KR100493932B1 (en) | Monoclonal antibody recognizing resistin, production method and use thereof | |
JPH10262662A (en) | Hoxime hapten compounds, antibodies and methods of measurement | |
JP4221119B2 (en) | Specific antibody against domoic acid and immunological analysis of domoic acid | |
JP4028925B2 (en) | Monoclonal antibody | |
JPH03139292A (en) | Monoclonal antibody against human interleukin 6 | |
JPS63209596A (en) | Monoclonal antibody and use thereof | |
JPS62299766A (en) | Monoclonal antibody and method for measuring 1-methyl adenosine using said antibody | |
JPH0543358B2 (en) | ||
RU2049816C1 (en) | Strain of hybrid cultured murine cells mus musculus l used for preparing monoclonal antibodies to thyroxine | |
JPH0438400B2 (en) |